Frank Podlaski

8.8k total citations · 3 hit papers
26 papers, 7.2k citations indexed

About

Frank Podlaski is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Frank Podlaski has authored 26 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 11 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Frank Podlaski's work include Immune Cell Function and Interaction (9 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Toxin Mechanisms and Immunotoxins (6 papers). Frank Podlaski is often cited by papers focused on Immune Cell Function and Interaction (9 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Toxin Mechanisms and Immunotoxins (6 papers). Frank Podlaski collaborates with scholars based in United States, Switzerland and Germany. Frank Podlaski's co-authors include Daisy Carvajal, Lyubomir T. Vassilev, Bradford Graves, Zoran Filipovic, Binh Thanh Vu, Norman Kong, Nader Fotouhi, U. Kammlott, Christine Lukacs and Emily A. Liu and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Frank Podlaski

26 papers receiving 7.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

2004 3.7k citations Lyubomir T. Vassilev, Binh Thanh Vu et al. Science profile →
Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells.

1990 579 citations A S Stern, Frank Podlaski et al. Proceedings of the National Academy of Sciences profile →
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

2013 447 citations Qingjie Ding, Zhuming Zhang et al. Journal of Medicinal Chemistry profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Frank Podlaski	3.8k	3.2k	2.1k	653	576	26	7.2k
Daisy Carvajal	3.7k 1.0×	3.1k 1.0×	1.8k 0.8×	631 1.0×	473 0.8×	18	6.5k
Allen Oliff	4.1k 1.1×	2.6k 0.8×	883 0.4×	562 0.9×	477 0.8×	107	6.7k
Shiro Akinaga	3.7k 1.0×	1.8k 0.5×	1.7k 0.8×	381 0.6×	470 0.8×	122	6.6k
James E. Strickler	3.4k 0.9×	1.0k 0.3×	1.3k 0.6×	608 0.9×	798 1.4×	47	6.1k
Christian Wiesmann	5.6k 1.5×	1.4k 0.4×	2.4k 1.1×	1.2k 1.9×	462 0.8×	67	8.8k
Heinz Läubli	2.6k 0.7×	1.8k 0.6×	2.1k 1.0×	442 0.7×	413 0.7×	95	4.9k
Doron C. Greenbaum	3.4k 0.9×	1.6k 0.5×	648 0.3×	1.0k 1.6×	935 1.6×	44	6.3k
Catherine L. Day	6.1k 1.6×	1.8k 0.6×	1.2k 0.6×	745 1.1×	328 0.6×	81	7.4k
Ralph B. Arlinghaus	5.4k 1.4×	1.9k 0.6×	1.1k 0.5×	735 1.1×	410 0.7×	250	10.7k
Andrea Anichini	3.3k 0.9×	3.3k 1.0×	4.4k 2.1×	611 0.9×	114 0.2×	198	7.9k

Countries citing papers authored by Frank Podlaski

Since Specialization

Citations

This map shows the geographic impact of Frank Podlaski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Podlaski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Podlaski more than expected).

Fields of papers citing papers by Frank Podlaski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Podlaski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Podlaski. The network helps show where Frank Podlaski may publish in the future.

Co-authorship network of co-authors of Frank Podlaski

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Podlaski. A scholar is included among the top collaborators of Frank Podlaski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Podlaski. Frank Podlaski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Podlaski, Frank, Kenny K. Wong, Brian A. McKittrick, et al.. (2023). Peptide Nucleic Acids Containing Cationic/Amino-Alkyl Modified Bases Promote Enhanced Hybridization Kinetics and Thermodynamics with Single-Strand DNA. ACS Omega. 8(37). 33426–33436. 8 indexed citations

Tovar, Christian, Bradford Graves, Kathryn Packman, et al.. (2013). MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models. Cancer Research. 73(8). 2587–2597. 220 indexed citations

Ding, Qingjie, Zhuming Zhang, Jinjun Liu, et al.. (2013). Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development. Journal of Medicinal Chemistry. 56(14). 5979–5983. 447 indexed citations breakdown →

Wartchow, Charles, Frank Podlaski, Shirley Xin Li, et al.. (2011). Biosensor-based small molecule fragment screening with biolayer interferometry. Journal of Computer-Aided Molecular Design. 25(7). 669–676. 107 indexed citations

Daouti, Sherif, Huisheng Wang, Wenhui Li, et al.. (2009). Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy. Cancer Research. 69(5). 1924–1932. 25 indexed citations

Vassilev, Lyubomir T., Binh Thanh Vu, Bradford Graves, et al.. (2004). In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. Science. 303(5659). 844–848. 3722 indexed citations breakdown →

Fry, David C., et al.. (2004). NMR structure of a complex between MDM2 and a small molecule inhibitor. Journal of Biomolecular NMR. 30(2). 163–173. 63 indexed citations

Podlaski, Frank & A S Stern. (2000). Site-Specific Immobilization of Antibodies to Protein G-Derivatized Solid Supports. Methods in molecular biology. 147. 41–48. 3 indexed citations

Wang, Xin, Victoria L. Wilkinson, Frank Podlaski, et al.. (1999). Characterization of mouse interleukin-12 p40 homodimer binding to the interleukin-12 receptor subunits. European Journal of Immunology. 29(6). 2007–2013. 48 indexed citations

10.

Mattner, Frank, Laurence Ozmen, Frank Podlaski, et al.. (1997). Treatment with homodimeric interleukin-12 (IL-12) p40 protects mice from IL-12-dependent shock but not from tumor necrosis factor alpha-dependent shock. Infection and Immunity. 65(11). 4734–4737. 70 indexed citations

11.

Gately, Maurice K., Daisy Carvajal, Suzanne E. Connaughton, et al.. (1996). Interleukin‐12 Antagonist Activity of Mouse Interleukin‐12 p40 Homodimer in Vitro and in Vivo. Annals of the New York Academy of Sciences. 795(1). 1–12. 118 indexed citations

12.

Germann, Tieno, Martina Bongartz, Henryka Długońska, et al.. (1995). Administration of IL-12 during ongoing immune responses fails to permanently suppress and can even enhance the synthesis of antigen-specific IgE. International Immunology. 7(10). 1649–1657. 44 indexed citations

13.

Germann, Tieno, Martina Bongartz, Henryka Długońska, et al.. (1995). Interleukin‐12 profoundly up‐regulates the synthesis of antigen‐specific complement‐fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. European Journal of Immunology. 25(3). 823–829. 299 indexed citations

14.

Gillessen, Silke, Daisy Carvajal, Ping Ling, et al.. (1995). Mouse interleukin‐12 (IL‐12) p40 homodimer: a potent IL‐12 antagonist. European Journal of Immunology. 25(1). 200–206. 391 indexed citations

15.

Germann, Tieno, Jacek Szeliga, Harald F. Hess, et al.. (1995). Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice.. Proceedings of the National Academy of Sciences. 92(11). 4823–4827. 179 indexed citations

16.

Shu, U., Christian E. Demeure, Dae‐Gyoo Byun, et al.. (1994). Interleukin 12 exerts a differential effect on the maturation of neonatal and adult human CD45R0- CD4 T cells.. Journal of Clinical Investigation. 94(4). 1352–1358. 39 indexed citations

17.

Demeure, Christian E., Maurice K. Gately, Frank Podlaski, et al.. (1994). In vitro maturation of human neonatal CD4 T lymphocytes. I. Induction of IL-4-producing cells after long-term culture in the presence of IL-4 plus either IL-2 or IL-12.. The Journal of Immunology. 152(3). 1141–1153. 66 indexed citations

18.

Podlaski, Frank, Venkata Nanduri, Jeffrey D. Hulmes, et al.. (1992). Molecular characterization of interleukin 12. Archives of Biochemistry and Biophysics. 294(1). 230–237. 90 indexed citations

19.

Chizzonite, R, Theresa Truitt, Frank Podlaski, et al.. (1991). IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. The Journal of Immunology. 147(5). 1548–1556. 95 indexed citations

20.

Hakimi, J, C Seals, Frank Podlaski, et al.. (1987). Biochemical and functional analysis of soluble human interleukin-2 receptor produced in rodent cells. Solid-phase reconstitution of a receptor-ligand binding reaction.. Journal of Biological Chemistry. 262(36). 17336–17341. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact